首页> 外文期刊>Radiochimica Acta: International Journal for Chemical Aspects of Nuclear Science and Technology >Preclinical dosimetric estimation of [In-111] 5, 10, 15, 20-tetra phenyl porphyrin complex as a possible imaging/PDT agent
【24h】

Preclinical dosimetric estimation of [In-111] 5, 10, 15, 20-tetra phenyl porphyrin complex as a possible imaging/PDT agent

机译:[In-111] 5、10、15、20-四苯基卟啉配合物作为可能的成像/ PDT剂的临床前剂量学估计

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Recent studies show that porphyrin derivatives have interesting pharmacological and photodynamic properties and wide range of usage in photodynamic therapy treatment. This study describes the preparation, biodistribution and absorbed dose prediction of [In-111] labeled 5, 10, 15, 20-tetra phenyl porphyrin (TPP) in human organs, based on rats' biodistribution data. Methods: Five rats were sacrificed at each exact time intervals (2, 4 and 24 h post injection) and the percentage of injected dose per gram of each organ was measured by direct counting from rats data from 12 harvested organs. The Medical Internal Radiation Dose (MIRD) formulation was applied to extrapolate from rats to human and to project the absorbed radiation dose for various organs in humans. Results: From rat data we estimated that injection of [In-111] TPP into the humans would result in an estimated effective absorbed dose of 0.09 mSv/MBq in the whole body. While the highest effective absorbed dose for In-111-TPP was in the heart wall (0.22 mSv), the organs that received the next highest doses were the Kidneys (0.06 mSv), thymus (0.04 mSv) and lungs (0.03 mSv). Conclusions: The skin dose will four times higher compare to the other In-111 compounds, which was due to magnificent skin uptakes. According to the fast wash-out, tumor avidity and the short half-life, [In-111] can be a suitable candidate for labeling of photo dynamic therapy (PDT) agents as a tracer for accurate biological evaluation of other PDT agents such as Photofrin and its homologs.
机译:简介:最近的研究表明,卟啉衍生物具有有趣的药理和光动力特性,并且在光动力疗法中有广泛的用途。这项研究基于大鼠的生物分布数据,描述了[In-111]标记的5、10、15、20-四苯基卟啉(TPP)在人体器官中的制备,生物分布和吸收剂量的预测。方法:在每个确切的时间间隔(注射后2、4和24小时)处死5只大鼠,并通过直接计数来自12个收获器官的大鼠数据来测量每克每个器官的注射剂量百分比。医学内部辐射剂量(MIRD)配方用于从大鼠外推到人体,并预测人体各器官吸收的辐射剂量。结果:根据大鼠数据,我们估计向人体内注射[In-111] TPP将导致整个身体的估计有效吸收剂量为0.09 mSv / MBq。 In-111-TPP的最高有效吸收剂量是在心脏壁(0.22 mSv),而第二高剂量的器官是肾脏(0.06 mSv),胸腺(0.04 mSv)和肺(0.03 mSv)。结论:皮肤剂量将比其他In-111化合物高四倍,这是由于大量摄取皮肤所致。根据快速清除,肿瘤亲和力和半衰期短的特点,[In-111]可以作为标记光动力疗法(PDT)试剂的合适候选物,作为对其他PDT试剂如Photofrin及其同系物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号